Antimicrobials Investment [Podcast]

“At a high level, I was interested in seeing all the buzz around vaccines and money being poured into those companies is if there was any other spillover into antibiotics, antifungals . . . 2020 saw a huge influx of capital into those spaces. But taking a double click into the antibiotic and antifungal space, there was a pretty substantial uptick last year.”

Dr. Peter Bak talks about the current landscape of anti-infectives, antimicrobials & antifungals, including:

• How commercial dynamics drive clinical unmet need

• The role the pandemic played on development & investments

• The deployment of cell therapies for viral diseases

• Foundation support for anti-infectives

• “Push incentives” to usher therapies into commercial stages